Alison Hannah
2021
In 2021, Alison Hannah earned a total compensation of $1.7M as Senior Vice President and Chief Medical Officer at CytomX Therapeutics, a 2% increase compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $190,404 |
---|---|
Option Awards | $887,172 |
Salary | $464,400 |
Stock Awards | $160,200 |
Other | $5,000 |
Total | $1,707,176 |
Hannah received $887.2K in option awards, accounting for 52% of the total pay in 2021.
Hannah also received $190.4K in non-equity incentive plan, $464.4K in salary, $160.2K in stock awards and $5K in other compensation.
Rankings
In 2021, Alison Hannah's compensation ranked 6,696th out of 12,415 executives tracked by ExecPay. In other words, Hannah earned more than 46.1% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 6,696 out of 12,415 | 46th |
Division Manufacturing | 2,901 out of 5,508 | 47th |
Major group Chemicals And Allied Products | 1,275 out of 2,378 | 46th |
Industry group Drugs | 1,137 out of 2,099 | 46th |
Industry Pharmaceutical Preparations | 827 out of 1,549 | 47th |
Source: SEC filing on April 27, 2022.
Hannah's colleagues
We found five more compensation records of executives who worked with Alison Hannah at CytomX Therapeutics in 2021.
2021
Sean McCarthy
CytomX Therapeutics
Chief Executive Officer
2021
Amy Peterson
CytomX Therapeutics
Chief Operating Officer
2021
Jeff Landau
CytomX Therapeutics
Senior Vice President and Chief Business Officer
2021
Lloyd Rowland
CytomX Therapeutics
General Counsel
2021
Carlos Campoy
CytomX Therapeutics